Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
Cetuximab/Paclitaxel/Cisplatin Concurrent Chemoradiotherapy Followed by Esophagectomy for Loco-regional Esophageal Cancer
- Conditions
- Esophageal Cancer
- Interventions
- First Posted Date
- 2009-12-17
- Last Posted Date
- 2009-12-17
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 62
- Registration Number
- NCT01034189
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors
- Conditions
- Tumors
- First Posted Date
- 2009-12-14
- Last Posted Date
- 2013-05-13
- Lead Sponsor
- University of California, San Francisco
- Registration Number
- NCT01031212
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2009-12-14
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 55
- Registration Number
- NCT01031446
- Locations
- 🇺🇸
Erlanger Cancer Center at Erlanger Hospital - Baroness, Chattanooga, Tennessee, United States
🇺🇸West Tennessee Cancer Center at Jackson-Madison County General Hospital, Jackson, Tennessee, United States
🇺🇸Baptist Regional Cancer Center at Baptist Riverside, Knoxville, Tennessee, United States
A Randomized Trial Comparing EC-wPversus EP-wP as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years Old
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 521
- Registration Number
- NCT01026116
- Locations
- 🇨🇳
Department of Breast Surgery, Cancer Hospital, Fudan University, Shanghai, China
Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- Lung Cancer
- First Posted Date
- 2009-12-03
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Target Recruit Count
- 26
- Registration Number
- NCT01024712
- Locations
- 🇨🇳
Cancer Institute Hospital, Chinese Academy of Medical Sciences, Beijing, China
Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2010-02-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 68
- Registration Number
- NCT01023204
Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2011-04-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 60
- Registration Number
- NCT01024062
Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck Cancer
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2011-04-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 36
- Registration Number
- NCT01024101
Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies
- Conditions
- Advanced Cancer
- Interventions
- First Posted Date
- 2009-11-18
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 122
- Registration Number
- NCT01015222
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer
- Conditions
- Ovarian NeoplasmsPeritoneal Neoplasms
- Interventions
- First Posted Date
- 2009-11-18
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1366
- Registration Number
- NCT01015118
- Locations
- 🇺🇸
1199.15.10019 Boehringer Ingelheim Investigational Site, Bismarck, North Dakota, United States
🇺🇸1199.15.10024 Boehringer Ingelheim Investigational Site, Canton, Ohio, United States
🇺🇸1199.15.10107 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.